Phase‐Dependent Antitumor Activity of Manganese Sulfide Nanomaterials
Source abstract
Abstract
Crystal polymorph engineering represents a pivotal strategy for enhancing the antitumor efficacy of pharmaceuticals. Current investigations on crystal engineering of antitumor agents are predominantly focused on organic small‐molecule drugs, whereas the correlation between crystal structure and bioactivity in inorganic nanomaterials remains underexplored. Herein, we report a comparative study on two crystalline polymorphs of manganese sulfide (MnS), α ‐MnS and γ ‐MnS, to unravel their distinct antitumor performances. Compared with γ ‐MnS, α ‐MnS demonstrates superior capacity in inducing intracellular reactive oxygen species (ROS) generation, leading to enhanced cytotoxicity against 4T1, A549, and MCF‐7 tumor cells. In a 4T1 tumor‐bearing mouse model, α ‐MnS treatment significantly reduces tumor volume relative to γ ‐MnS, while maintaining excellent biosafety profiles. These findings shed light on the structure–activity relationship of inorganic nanomaterials, providing a novel theoretical paradigm for the rational design of high‐performance nanotherapeutics with precise crystal form‐bioactivity matching.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Metal-Organic Frameworks: Synthesis and Applications · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Jiangsu Collaborative Innovation Center of Biomedical Functional Materials Jiangsu Key Laboratory of New Power Batteries School of Chemistry and Materials Science Nanjing Normal University Nanjing China
National University of Singapore Suzhou Research Institute Suzhou China
References (41)
Show source-provided references
1. 10.1016/j.addr.2016.12.00110.1016/j.addr.2016.12.001 ↗
2. 10.1016/j.ijpharm.2020.11969410.1016/j.ijpharm.2020.119694 ↗
3. 10.1016/j.lwt.2024.11598410.1016/j.lwt.2024.115984 ↗
4. In Vivo Biodistribution, Biocompatibility, and Efficacy of Sorafenib‐Loaded Lipid‐Based Nanosuspensions Evaluated Experimentally in Cancer
5. Implanted Microneedles Loaded with Sparfloxacin and Zinc‐Manganese Sulfide Nanoparticles Activates Immunity for Postoperative Triple‐Negative Breast Cancer to Prevent Recurrence and Metastasis
6. 10.1186/s13045-021-01096-010.1186/s13045-021-01096-0 ↗
7. 10.1002/cac2.1225510.1002/cac2.12255 ↗
8. 10.1038/s41392-024-01889-y10.1038/s41392-024-01889-y ↗
9. 10.2217/nnm-2022-018710.2217/nnm-2022-0187 ↗
10. 10.1002/adfm.20241768110.1002/adfm.202417681 ↗
11. Nanozymes: A Comprehensive Review on Emerging Applications in Cancer Diagnosis and Therapeutics
12. 10.1016/j.bioactmat.2022.01.01010.1016/j.bioactmat.2022.01.010 ↗
13. 10.1002/adma.20250336110.1002/adma.202503361 ↗
14. 10.1021/acscatal.4c0614210.1021/acscatal.4c06142 ↗
15. 10.34133/bmr.015810.34133/bmr.0158 ↗
16. 10.1016/j.freeradbiomed.2015.10.41610.1016/j.freeradbiomed.2015.10.416 ↗
17. 10.1016/j.actbio.2022.10.01810.1016/j.actbio.2022.10.018 ↗
18. 10.1186/s12951-021-01074-110.1186/s12951-021-01074-1 ↗
19. 10.1186/s12951-025-03469-w10.1186/s12951-025-03469-w ↗
20. 10.1021/acsnano.3c0817410.1021/acsnano.3c08174 ↗
21. 10.1021/acsnano.4c1558710.1021/acsnano.4c15587 ↗
22. 10.1002/smll.20240111710.1002/smll.202401117 ↗
23. 10.1021/acsnano.3c0901110.1021/acsnano.3c09011 ↗
24. 10.1021/acsnano.2c0085410.1021/acsnano.2c00854 ↗
25. 10.1021/acsnano.9b0420510.1021/acsnano.9b04205 ↗
26. 10.1007/s10854-018-9179-910.1007/s10854-018-9179-9 ↗
27. 10.1107/S002188981103897010.1107/S0021889811038970 ↗
28. 10.1016/j.bioactmat.2022.04.01110.1016/j.bioactmat.2022.04.011 ↗
29. 10.1021/es061780010.1021/es0617800 ↗
30. 10.1002/smll.20240249610.1002/smll.202402496 ↗
31. 10.1063/5.000704510.1063/5.0007045 ↗
32. 10.1016/j.cattod.2014.07.00910.1016/j.cattod.2014.07.009 ↗
33. 10.1016/j.jmrt.2025.08.08210.1016/j.jmrt.2025.08.082 ↗
34. 10.1016/j.jece.2025.11780110.1016/j.jece.2025.117801 ↗
35. 10.1039/D4NH00109E10.1039/D4NH00109E ↗
36. 10.1016/j.jece.2025.11695410.1016/j.jece.2025.116954 ↗
37. 10.1021/jacs.4c1469510.1021/jacs.4c14695 ↗
38. 10.3390/cancers402044210.3390/cancers4020442 ↗
39. Redox Regulation by Intrinsic Species and Extrinsic Nutrients in Normal and Cancer Cells
40. 10.1002/med.2173410.1002/med.21734 ↗
41. 10.1016/j.jcis.2023.12.04210.1016/j.jcis.2023.12.042 ↗